Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited - Université de Tours Accéder directement au contenu
Article Dans Une Revue Clinical Pharmacokinetics Année : 2019

Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited

Résumé

Rituximab is approved in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and leads to a decrease of ANCA levels. The objectives of this study were to investigate the non-linear pharmacokinetics of rituximab and the relationship between its concentrations and ANCA levels in AAV patients.

Domaines

Immunologie
Fichier non déposé

Dates et versions

hal-02316414 , version 1 (15-10-2019)

Identifiants

Citer

Amina Bensalem, Denis Mulleman, Gilles Paintaud, Nicolas Azzopardi, Valerie Gouilleux-Gruart, et al.. Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited. Clinical Pharmacokinetics, 2019, ⟨10.1007/s40262-019-00826-5⟩. ⟨hal-02316414⟩
186 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More